Loading contract…
BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
Direct supply and administration of Lecanemab (Leqembi) in a patient’s home, via a homecare delivery service. Lecanemab is indicated for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients that are apolipoprotein E ε 4 (ApoE ε 4) heterozygotes or non-carriers. The service is being offered by UCLH private Healthcare and will be for private patients only.
No supplier information available.
This procurement was divided into 1 lots, each awarded separately.
| Lot | Value | Status |
|---|---|---|
| Lot 1 720 days (≈2 yrs) | - | active |
Published by the buyer on this notice. Details change and are not updated here.